Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) was upgraded by research analysts at Vetr from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Monday. The brokerage presently has a $142.00 price objective on the biopharmaceutical company’s stock. Vetr‘s price target would indicate a potential upside of 24.98% from the stock’s current price.

ALXN has been the topic of a number of other research reports. Leerink Swann reiterated a “buy” rating and issued a $200.00 price target on shares of Alexion Pharmaceuticals in a research report on Sunday, July 17th. Piper Jaffray Cos. set a $176.00 price target on Alexion Pharmaceuticals and gave the company a “buy” rating in a research report on Sunday, November 6th. Zacks Investment Research lowered Alexion Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Wednesday, November 2nd. Deutsche Bank AG initiated coverage on Alexion Pharmaceuticals in a research report on Thursday, November 3rd. They issued a “buy” rating and a $164.00 price target on the stock. Finally, Citigroup Inc. upped their price target on Alexion Pharmaceuticals from $154.00 to $155.00 and gave the company a “buy” rating in a research report on Tuesday, September 20th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $173.36.

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) opened at 113.62 on Monday. The stock’s 50 day moving average price is $123.79 and its 200 day moving average price is $130.71. The company has a market cap of $25.47 billion, a PE ratio of 69.28 and a beta of 1.45. Alexion Pharmaceuticals has a one year low of $110.56 and a one year high of $193.45.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, October 27th. The biopharmaceutical company reported $1.23 earnings per share for the quarter, topping analysts’ consensus estimates of $1.04 by $0.19. The business had revenue of $799 million for the quarter, compared to analyst estimates of $787.07 million. Alexion Pharmaceuticals had a return on equity of 10.58% and a net margin of 12.46%. Alexion Pharmaceuticals’s quarterly revenue was up 19.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.16 EPS. Equities analysts predict that Alexion Pharmaceuticals will post $4.64 earnings per share for the current fiscal year.

In other Alexion Pharmaceuticals news, Director Alvin S. Parven sold 15,000 shares of the stock in a transaction on Monday, August 22nd. The stock was sold at an average price of $136.53, for a total transaction of $2,047,950.00. Following the completion of the transaction, the director now directly owns 6,373 shares of the company’s stock, valued at $870,105.69. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Leonard Bell sold 1,300 shares of the stock in a transaction on Monday, October 31st. The shares were sold at an average price of $135.28, for a total value of $175,864.00. Following the transaction, the director now directly owns 406,589 shares of the company’s stock, valued at $55,003,359.92. The disclosure for this sale can be found here. Company insiders own 4.41% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the stock. FMR LLC increased its stake in Alexion Pharmaceuticals by 12.0% in the second quarter. FMR LLC now owns 18,745,795 shares of the biopharmaceutical company’s stock valued at $2,188,759,000 after buying an additional 2,002,085 shares in the last quarter. Vanguard Group Inc. increased its stake in Alexion Pharmaceuticals by 1.6% in the second quarter. Vanguard Group Inc. now owns 13,478,718 shares of the biopharmaceutical company’s stock valued at $1,573,774,000 after buying an additional 216,269 shares in the last quarter. Jennison Associates LLC increased its stake in Alexion Pharmaceuticals by 0.6% in the third quarter. Jennison Associates LLC now owns 7,137,235 shares of the biopharmaceutical company’s stock valued at $874,597,000 after buying an additional 43,840 shares in the last quarter. Ameriprise Financial Inc. increased its stake in Alexion Pharmaceuticals by 13.7% in the second quarter. Ameriprise Financial Inc. now owns 6,025,775 shares of the biopharmaceutical company’s stock valued at $703,575,000 after buying an additional 728,182 shares in the last quarter. Finally, BlackRock Institutional Trust Company N.A. increased its stake in Alexion Pharmaceuticals by 5.0% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 5,971,101 shares of the biopharmaceutical company’s stock valued at $731,699,000 after buying an additional 284,747 shares in the last quarter. 96.38% of the stock is owned by institutional investors and hedge funds.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

5 Day Chart for NASDAQ:ALXN

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.